Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

Cancer Cell
Sheng-Bin PengDaniel L Flynn

Abstract

LY3009120 is a pan-RAF and RAF dimer inhibitor that inhibits all RAF isoforms and occupies both protomers in RAF dimers. Biochemical and cellular analyses revealed that LY3009120 inhibits ARAF, BRAF, and CRAF isoforms with similar affinity, while vemurafenib or dabrafenib have little or modest CRAF activity compared to their BRAF activities. LY3009120 induces BRAF-CRAF dimerization but inhibits the phosphorylation of downstream MEK and ERK, suggesting that it effectively inhibits the kinase activity of BRAF-CRAF heterodimers. Further analyses demonstrated that LY3009120 also inhibits various forms of RAF dimers including BRAF or CRAF homodimers. Due to these unique properties, LY3009120 demonstrates minimal paradoxical activation, inhibits MEK1/2 phosphorylation, and exhibits anti-tumor activities across multiple models carrying KRAS, NRAS, or BRAF mutation.

References

Jun 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·C J DerG M Cooper
Jun 18, 2002·Nature·Helen DaviesP Andrew Futreal
Mar 24, 2004·Cell·Paul T C WanUNKNOWN Cancer Genome Project
Nov 8, 2005·Nature·David B SolitNeal Rosen
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
Feb 22, 2008·Proceedings of the National Academy of Sciences of the United States of America·James TsaiGideon Bollag
Nov 18, 2008·Cancer Research·Christine A PratilasDavid B Solit
Sep 8, 2010·The New England Journal of Medicine·Keith T FlahertyPaul B Chapman
Apr 2, 2011·The Journal of Biological Chemistry·Angela BaljulsUlf R Rapp
Apr 13, 2011·Cancer Cell·Leisl Packer, Richard Marais
Jun 7, 2011·The New England Journal of Medicine·Paul B ChapmanUNKNOWN BRIM-3 Study Group
Jun 28, 2011·Chemistry & Biology·Matthew P PatricelliJohn W Kozarich
Oct 14, 2011·Nature Reviews. Cancer·Yuliya Pylayeva-GuptaDafna Bar-Sagi
Jun 6, 2012·The New England Journal of Medicine·Keith T FlahertyUNKNOWN METRIC Study Group
Jul 20, 2012·Journal of Medicinal Chemistry·Xiaolun Wang, Joseph Kim
Oct 13, 2012·Nature Reviews. Drug Discovery·Gideon BollagPeter Hirth
Jan 29, 2013·Molecular Cell·Alyson K FreemanDeborah K Morrison
May 18, 2013·Cancer Cell·Matthew HolderfieldTobi E Nagel
Sep 3, 2013·Cell·Jiancheng HuAndrey S Shaw
Sep 10, 2014·Cell Reports·Simona LambaAlberto Bardelli
Oct 18, 2014·Nature Reviews. Drug Discovery·Adrienne D CoxChanning J Der

❮ Previous
Next ❯

Citations

Feb 20, 2016·Cellular and Molecular Life Sciences : CMLS·Fuquan Zhang, Jit Kong Cheong
Jan 26, 2016·Pharmacology & Therapeutics·Rebecca A Jackson, Ee Sin Chen
May 9, 2016·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Galia Maik-Rachline, Rony Seger
Mar 19, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Ha Linh Vu, Andrew E Aplin
Sep 17, 2015·Cancer Cell·Robert L Kortum, Deborah K Morrison
Apr 21, 2016·Cancers·Daniel ZeitouniKirsten L Bryant
Oct 23, 2016·Cellular and Molecular Life Sciences : CMLS·David LakeJürgen Müller
Aug 30, 2016·Medicinal Research Reviews·Antoine MilletRachid Benhida
Mar 18, 2017·Science·Bjoern Papke, Channing J Der
Jan 24, 2017·The Cancer Journal·Wade T IamsSunandana Chandra
Oct 7, 2017·Nature Reviews. Cancer·Zoi KarouliaPoulikos I Poulikakos
Apr 4, 2017·Organic & Biomolecular Chemistry·Lu WangWeifang Tang
May 23, 2018·Melanoma Management·Ileabett M Echevarría-Vargas, Jessie Villanueva
Jul 12, 2018·Chembiochem : a European Journal of Chemical Biology·Nicholas CopeZhihong Wang
Dec 13, 2017·Cold Spring Harbor Perspectives in Medicine·Andrew M Waters, Channing J Der
Jan 14, 2018·Scientific Reports·Monica MarzagalliPatrizia Limonta
Feb 20, 2018·Molecular Cancer·Wagner Ricardo MontorFabiana Henriques Machado de Melo
Apr 27, 2019·Expert Opinion on Pharmacotherapy·Robert MasonJames Larkin
Dec 14, 2017·British Journal of Cancer·David E Durrant, Deborah K Morrison
Jul 17, 2019·Journal of Enzyme Inhibition and Medicinal Chemistry·Jinwoong KimJung-Mi Hah
Jan 10, 2019·The Journal of Pharmacology and Experimental Therapeutics·Gautham GampaWilliam F Elmquist
Aug 3, 2019·Expert Opinion on Therapeutic Patents·Ruo-Jun ManHai-Liang Zhu
Jun 2, 2016·American Society of Clinical Oncology Educational Book·Giles W RobinsonAdam Resnick
Dec 10, 2019·Current Opinion in Pediatrics·Angelina V Vaseva, Marielle E Yohe
Jan 17, 2020·Cells·Ufuk DegirmenciJiancheng Hu
Sep 22, 2019·Cell Death and Differentiation·Kristina RiegelKrishnaraj Rajalingam
Aug 19, 2020·Journal of Hematology & Oncology·Jimin YuanJiancheng Hu
Apr 11, 2018·Small GTPases·John C RoseDustin J Maly
Jul 19, 2017·Therapeutic Advances in Medical Oncology·Amélie BoespflugLuc Thomas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.